To assess the effect of antenatal corticosteroids on very low birth weight (VLBW) infants through 36 weeks' postconceptional age.
In 1972, Liggens and Howie 1 first reported the use of antenatal corticosteroid therapy (ANS) for the prevention of respiratory distress syndrome (RDS) in premature infants. Meta-analysis of subsequent studies conducted in the 1970s and 1980s noted not only a lower frequency of RDS but also an increased neonatal survival rate, a decrease in the frequency of intraventricular hemorrhage (IVH), and no clear-cut evidence of adverse effects. 2 Despite published data demonstrating the efficacy of ANS, Ͻ20% of women in the United States in preterm labor received ANS in 1992. 3 Although ANS use has increased since the panel of the 1994 National Institutes of Health Consensus Conference on the Effect of Corticosteroids for Fetal Maturation and Perinatal Outcomes recommended the use of corticosteroids for the majority of women in premature labor, ϳ45% of women in preterm labor did not receive ANS in 1996. 3 Although the primary focus of most published clinical studies of ANS has been the prevention of RDS, animal and human data indicate that corticosteroids induce maturation of other organ systems besides the lung. 4 Our study focused on assessing the efficacy of ANS in reducing the frequency of neonatal morbidities associated with prematurity, other than RDS. We specifically looked at chronic lung disease (CLD), IVH, cystic periventricular leukomalacia (PVL), patent ductus arteriosus (PDA), surgery for retinopathy of prematurity, and mortality. We also reviewed the association of corticosteroids with necrotizing enterocolitis (NEC) and neonatal sepsis.
METHODS
All very low birth weight (VLBW) infants admitted to the newborn intensive care unit at the University of New Mexico Hospital between May of 1991 and July of 1996 were included. Clinical and demographic data were collected prospectively as part of the National Institute of Child Health and Human Development Neonatal Research Database. Data were collected according to standardized definitions for each item by Network research nurses and were validated by independent review. 5 ANS consisted of a single course of betamethasone. A complete course consisted of two doses of betamethasone (12.5 mg) 12 hours apart, given before delivery, and an incomplete course, if only one dose was given. Before 1995, ANS was given at the discretion of the attending obstetrician. Since 1995, all pregnant women at risk for delivery between 24 and 34 weeks' gestation were eligible to receive ANS unless their pregnancy was complicated by chorioamnionitis,
tuberculosis, or viral keratitis. In our population, 77% of the infants with ANS were exposed to a complete course of therapy. CLD was defined as a need for continuous oxygen therapy at 36 weeks' postconceptional age (by best obstetric measurements). Only PDA that required indomethacin therapy and/or surgical ligation was included. NEC was defined as Bell stage II or III. 6 Sepsis was classified as early, if bacteria were noted in a blood culture obtained at Ͻ72 hours postnatal age, and late, if a positive culture was reported at any time beyond 72 hours postnatal age.
Infants were screened routinely for IVH by cranial sonography at 5 to 10 days of age. IVH was classified according to Papile et al. 7 Repeat sonograms were obtained on all infants with grades 2 through 4 IVH, on any infants who had increased echogenicity in the brain parenchyma, and on infants whose clinical course indicated followup. PVL was defined as the presence of periventricular cysts unrelated to IVH. All sonograms were read by a single pediatric radiologist.
Data were analyzed using the SAS Statistical Software Package (SAS Institute, Cary, NC) and StatXact (Cytel Software Corporation, Cambridge, MA). Continuous variables were compared by Student's t-test. Discrete variables were compared with Fisher's exact test. Due to the skewed distribution of length of hospital stay, analysis was performed on the logarithmtransformed data. In this case, both means and 95% confidence intervals (CI) were transformed back by exponentiation. Stepwise logistic regression was used to assess the relationship between maternal and infant variables and neonatal outcomes. Odds ratios (OR) and CI were calculated.
RESULTS
Selected demographic and clinical data are shown in Table 1 . There were no significant differences between the corticosteroid-exposed and nonexposed maternal groups and the frequency of premature rupture of the membranes or antepartum hemorrhage. The women who received steroids were significantly older ( p ϭ 0.01), were more likely to have preeclampsia/hypertension ( p Ͻ 0.01), and were more likely to be delivered by cesarean section ( p ϭ 0.04). There were no significant differences with regard to gestational age, birth weight, sex, and the need for surfactant therapy or postnatal steroid therapy between the infant groups.
Infant outcomes are outlined in Table 2 . There were no differences between the groups in the frequency of PDA, NEC, early or late sepsis, retinopathy of prematurity requiring surgery, or length of hospital stay. Steroid-exposed infants had a significantly lower mortality rate ( p ϭ 0.02). There was also a significant favorable impact on Apgar scores at 1 minute ( p Ͻ 0.01) and 5 minutes ( p Ͻ 0.01). Although the frequency of CLD was not statistically different between the groups ( p ϭ 0.48), a significantly greater proportion of surviving steroid-exposed infants did not have CLD; the combined outcome of CLD and death from respiratory causes was significantly less in the steroid-exposed group ( p ϭ 0.02) (Figure 1) .
Cranial sonograms were obtained on 532 of the 574 surviving infants (93%). All of the surviving infants who were not screened for IVH were transferred to a level 2 facility before 5 to 10 days of age. There were no significant differences in the overall frequency of IVH and PVL. Although not statistically different ( p ϭ 0.08), the proportion of steroid-exposed infants with grades 3 and 4 IVH was 50% less than nonexposed infants (4% vs 9%).
Stepwise logistic regression analyses were performed to ascertain which maternal characteristics had an impact on neonatal mortality and medical morbidity, adjusting for birth weight, gestational age, and sex (Table 3) 
DISCUSSION
Our center's use of ANS therapy increased from ϳ16% in 1993 to 84% in 1996. We were particularly interested in what the global impact of ANS had been on our VLBW infants, especially since the advent of surfactant therapy. We found that any steroid use positively impacted our VLBW population. ANS was associated with a 50% decrease in the mortality rate. It also significantly increased Apgar scores, as others have reported. 8 Interestingly, the use of exogenous surfactant therapy for acute respiratory distress (RDS) did not differ between the groups ( p ϭ 1.00). Although previous investigators have noted that antenatal steroid therapy is associated with a lower frequency of RDS, 2 the lack of efficacy that we noted may be due to the nature of our center and the high-risk maternal population referred here.
Despite a similar frequency of surfactant therapy for RDS, significantly fewer steroid-exposed infants developed CLD or died from respiratory causes. In addition, the frequency of CLD among surviving infants did not differ between the groups. Maternal preeclampsia/ hypertension also was associated with less CLD. Because significantly more women with preeclampsia/hypertension received steroids, we are unable to attribute the reduction in CLD solely to the use of antenatal steroids.
Although, steroid-exposed infants had a lower frequency of severe IVH, the difference was not significant ( p ϭ 0.08). In contrast to the findings of Van de Bor et al., 9 we did not find that preeclampsia/hypertension significantly reduced the risk of IVH; however, it could be a source of confounding. Other possible confounding factors such as the use of antenatal magnesium sulfate or indomethacin were not considered in this study. 10, 11 However, a recent report suggests that antenatal magnesium exposure is not associated with any reduction in the frequency of severe IVH. 12 Antenatal indomethacin may increase the risk of severe IVH. 13 In contrast to Kari et al., 14 we found no difference in the occurrence of cystic PVL between the groups. Our definition of PVL, unlike that of Kari et al., did not include porencephalic lesions attributable to IVH.
The effect of ANS on NEC and neonatal infection remains controversial.
2 Within our population, there was no significant increase in sepsis (early or late) with steroid use. Given our clinical practice of relatively early enteral feeding, there was no significant increase in NEC. In addition, the number of infants who required medical or surgical intervention for PDA or surgeries for retinopathy of prematurity did not differ between the groups. Although more infants survived with ANS, they did not have a longer hospital stay.
Postnatal steroids were used only for infants of Ͼ2 weeks of age who had compromised lungs and ventilator dependency. Thus, postnatal steroids were associated with CLD, as was surfactant, which was given only on an acuity basis.
Our analysis has the inherent limitations of retrospective studies. We did not control the selection of women to receive ANS. In addition, the use of ANS increased dramatically in the last half of the study. The total maternal population treated with ANS included those with fetal deaths and live born infants with a birth weight of Ͼ1500 gm. However, our analysis included all live-born VLBW infants, the majority of at-risk premature infants.
In conclusion, we noted that ANS is associated with an increased chance of survival for VLBW infants without a significant increase in medical morbidity. Higher Apgar scores reflected less need for delivery room intervention, and a decrease in the risk for CLD or death due to respiratory causes contributed to a more favorable outcome.
